Cargando…

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran

Idarucizumab (Praxbind) is a humanized antibody fragment, that reversibly and with high affinityties up dabigatran (Pradaxa). Anticoagulation reversal is achieved immediately, and with no procoagulant effect. It is administered intravenously and clearance is renal. The main clinical application of i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giannandrea, David, Mengoni, Anna, Carluccio, Erberto, Ambrosio, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536811/ https://www.ncbi.nlm.nih.gov/pubmed/31213821 http://dx.doi.org/10.2147/VHRM.S181806

Ejemplares similares

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
por: Sié, Pierre
Publicado: (2016)

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
por: Proietti, Marco, et al.
Publicado: (2018)

Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
por: Grottke, Oliver, et al.
Publicado: (2016)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

Idarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report
por: Jia, Yu, et al.
Publicado: (2022)

Reversal of Anticoagulation Effect of Dabigatran with Idarucizumab, for Thrombolysis in Acute Ischemic Stroke: Inimicus Inimico Amicus
por: Maramattom, Boby V., et al.
Publicado: (2019)

Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
por: Grottke, Oliver, et al.
Publicado: (2014)

Practical Guide for Anticoagulant and Antiplatelet Reversal in Clinical Practice
por: Aldhaeefi, Mohammed, et al.
Publicado: (2023)

Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
por: Agosti, Sergio, et al.
Publicado: (2017)

Idarucizumab: A novel antidote for reversal of dabigatran
por: Rehman, Abdul, et al.
Publicado: (2016)

Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage
por: Balakumar, Jonathan, et al.
Publicado: (2017)

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
por: Glund, Stephan, et al.
Publicado: (2018)

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study
por: Yasaka, Masahiro, et al.
Publicado: (2020)

New options with dabigatran etexilate in anticoagulant therapy
por: Maegdefessel, Lars, et al.
Publicado: (2010)

Promise and challenges of anticoagulation with dabigatran
por: Verma, Ashish, et al.
Publicado: (2012)

Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies
por: Carluccio, Erberto, et al.
Publicado: (2023)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)

Reversal of direct oral anticoagulants
por: Almegren, Mosaad
Publicado: (2017)

Extensive spontaneous cervical epidural hematoma due to oral anticoagulant (dabigatran) successfully treated with reversal agent idarucizumab alone
por: Uddin, Syed-Abdullah, et al.
Publicado: (2022)

Anticoagulant Related Nephropathy Induced by Dabigatran
por: Sharfuddin, Nazia, et al.
Publicado: (2018)

Emergency Reversal of Anticoagulation
por: Yee, Jennifer, et al.
Publicado: (2019)

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
por: Kafke, Waldemar, et al.
Publicado: (2016)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
por: Abdulrehman, Jameel, et al.
Publicado: (2021)

In a trauma experimental pig model prothrombin complex concentrates and a specific antidote (idarucizumab) are effective to reverse the anticoagulant effects of dabigatran
por: Grottke, O, et al.
Publicado: (2014)

Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice
por: Sauter, Thomas C., et al.
Publicado: (2016)

Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
por: Gendron, Nicolas, et al.
Publicado: (2017)

A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
por: Joppa, Stephanie A., et al.
Publicado: (2018)

HIV cure trial mergers: Spotlighting the epigenetics of latency reversal
por: Denton, Paul W.
Publicado: (2022)

Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia
por: Kairov, Gaisa T., et al.
Publicado: (2018)

Delayed concentration effect models for dabigatran anticoagulation
por: Eaton, Michael P., et al.
Publicado: (2022)

Non-invasive assessment of acute heart failure by Stevenson classification: Does echocardiographic examination recognize different phenotypes?
por: Palazzuoli, Alberto, et al.
Publicado: (2022)

Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
por: Bellamy, L, et al.
Publicado: (2009)

Dental management of patients taking novel oral anticoagulants (NOAs): Dabigatran
por: Curto, Adrian, et al.
Publicado: (2017)

Reversal of the Anticoagulation Effects of Dabigatran Etexilate by Idarucizumab in Three Patients Needing Urgent Surgical Intervention and One Case of Intravenous Thrombolysis in Ischaemic Stroke
por: von Wowern, Fredrik, et al.
Publicado: (2017)

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
por: Hieber, Maren, et al.
Publicado: (2019)

Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab
por: Riario Sforza, Gian Galeazzo, et al.
Publicado: (2018)

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
por: Norris, Stephen, et al.
Publicado: (2017)

Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature
por: Frol, Senta, et al.
Publicado: (2021)

The Reversal of Direct Oral Anticoagulants in Animal Models
por: Honickel, Markus, et al.
Publicado: (2017)

Reversal of Anticoagulants in Critical Care
por: Chacko, Binila, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r9t5418ttjtlmn8psfdt6jp0g8